CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
Bupivicaine +1 moredrug
Likely dose
Bupivicaine 30 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01444924
NCT01444924Phase 2Completed
CompareCT.gov

Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial

University of Wisconsin, Madison·interventional·Posted Oct 3, 2011·Updated Nov 27, 2019

In Brief

A Phase 2 clinical trial evaluating Bupivicaine and Placebo for Gynecologic Cancer and Post-operative Pain. Completed, enrolled 75 participants across 1 site.

Detailed Summary

This study is a single-center, randomized, placebo-controlled, double-blind clinical trial. The purpose of this study is to evaluate the impact of pre-operative transverses abdominis plane (TAP) blocks on post-operative analgesia in patients undergoing robotic surgery for gynecologic cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecologic Cancer, Post-operative Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 3, 2011
Enrollment StartSep 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.7 years ago

Interventions

Bupivicainedrug

The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis

Placebodrug

The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.